Fulcrum Therapeutics
FULC | NASDAQ
$3.71
-$0.06 (-1.59%)
At close: Nov 16, 2026, 4:00 PM ET
$3.72
+$0.01 (+0.27%)
After-hours:
Nov 16, 2026, 5:58 PM ET
Fulcrum Therapeutics Company Profile
Company profile explainedCompany Profile
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Alexander C. Sapir | Chief Executive Officer, President & Director |
| Curtis G. Oltmans | Chief Legal Officer, Head of External Affairs & Corporate Secretary |
| Alan A. Musso | CFO, Treasurer & Principal Accounting Officer |
| Bobby Riehle | Head of Program Strategy & Vice President |
| Bradley E. Bernstein | Founder |
| Danny Reinberg | Founder |
| Iain Fraser DPHIL | Senior Vice President of Early Development |
| Lisa Percival | Chief Regulatory & Quality Assurance Officer |
| Michael R. Green | Founder |
| Rudolf Jaenisch | Founder |
| Tsun-Huei Lee | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 20, 2026 | S-4/A | [Amend] Filing |
| Oct 08, 2026 | S-4/A | [Amend] Filing |
| Sep 02, 2026 | S-4 | Filing |
| Aug 17, 2026 | 425 | Filing |
| Aug 17, 2026 | 425 | Filing |
| Aug 17, 2026 | 425 | Filing |
| Aug 17, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Fulcrum Therapeutics
| Country | United States |
| IPO Date | Jul 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Alexander C. Sapir |
Contact Details
26 Landsdowne Street Cambridge,
Massachusetts 02139 United States
Stock Details
| Ticker Symbol | FULC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001680581 |
| CUSIP Number | 359616109 |
| ISIN Number | US3596161097 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove FULC